Serum IL-33 Levels Are Associated with Liver Damage in Patients with Chronic Hepatitis C
Figure 4
The changes in the levels of serum IL-33 and sST2 in CHC patients with IFN treatment. Data are expressed as the mean values of individual participants from two separate experiments. The horizontal lines show the median. (a) The changes in the levels of serum IL-33 in CHC patients with IFN treatment; (b) the changes in the levels of serum sST2 in CHC patients with IFN treatment.
